News about Clinical Trials

Teva's Olanzapine LAI Shows Long-Term Schizophrenia Efficacy

Teva’s TEV-’749 olanzapine LAI showed high stabilisation rates, low relapse and long-term remission in a phase 3 SOLARIS trial analysis.

Clinical Trials | 22/09/2026 | By News Bureau

Teva's UZEDY Outperforms LAIs in Schizophrenia Care

Teva Pharmaceuticals shows new real-world data showing UZEDY outperforms other Long-Acting Injectables in treatment adherence, reducing ER visits and costs.

Clinical Trials | 21/09/2026 | By News Bureau

Avacta Reports Early Clinical Validation of AVA6103 in FOCUS-01 Trial

Avacta’s early FOCUS-01 data provide clinical validation for AVA6103 and support further evaluation of its pre|CISION tumour-activated PDC platform.

Clinical Trials | 21/09/2026 | By News Bureau |  120

Longeveron's Laromestrocel Trial Misses Primary Endpoint in HLHS

Longeveron’s investigational stem cell therapy laromestrocel did not meet the primary efficacy endpoint in the Phase 2b ELPIS 2 trial evaluating infants with hypoplastic left heart syndrome.

Clinical Trials | 21/09/2026 | By News Bureau

Novo's Denecimig Tolerable After Switch From Emicizumab

Novo's denecimig shows tolerability after switching from emicizumab in the FRONTIER5 hemophilia A study, published in Journal of Thrombosis and Haemostasis.

Clinical Trials | 19/09/2026 | By News Bureau

Roche's Lunsumio Combo Meets Phase 3 CELESTIMO Endpoint

Roche’s Phase 3 CELESTIMO study shows statistically significant, clinically meaningful improvement in PFS with Lunsumio plus lenalidomide in R/R follicular lymphoma.

Clinical Trials | 18/09/2026 | By News Bureau

Sobi-Innate Pharma Partnership Advances Lacutamab Phase 3 Study

The partnership between Sobi and Innate Pharma will support the TELLOMAK-3 confirmatory Phase 3 trial in CTCL and development of lacutamab in Sézary syndrome.

Clinical Trials | 18/09/2026 | By News Bureau

Arrowhead Pharma Reports Interim Data on Dual RNAi Therapy

Arrowhead Pharmaceuticals has announced interim topline clinical data for the first dual-functional RNAi therapeutic for the treatment of mixed hyperlipidemia.

Clinical Trials | 17/09/2026 | By News Bureau

AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC

DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.

Clinical Trials | 16/09/2026 | By News Bureau

Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China

Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.

Clinical Trials | 15/09/2026 | By News Bureau